Expression analysis revealed that EDIL3 expression was elevated in many types of tumors, including hepatocellular carcinoma, pancreatic adenocarcinoma, colorectal cancer, and breast cancer (Jiang et al., 2016; Lee et al., 2018; Sun et al., 2010; Villar-Vazquez et al., 2016), while the expression of EDIL3 decreased in non-small cell lung cancer (Lee et al., 2015). Here, EDIL3 is linked to hepatocellular carcinoma.